155 related articles for article (PubMed ID: 33371164)
1. The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis.
Koh HM; Hyun CL; Jang BG; Lee HJ
Medicine (Baltimore); 2020 Dec; 99(51):e23837. PubMed ID: 33371164
[TBL] [Abstract][Full Text] [Related]
2. High Serum HDGF Levels Are Predictive of Bone Metastasis and Unfavorable Prognosis in Non-Small Cell Lung Cancer.
Zhang G; Liu Z; Chen Y; Zhang Y
Tohoku J Exp Med; 2017 Jun; 242(2):101-108. PubMed ID: 28592712
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of hepatoma-derived growth factor in solid tumors of Eastern Asia: a systematic review and meta- analysis.
Bao CH; Liu K; Wang XT; Ma W; Wang JB; Wang C; Jia YB; Wang NN; Tan BX; Song QX; Cheng YF
Asian Pac J Cancer Prev; 2015; 16(5):1803-11. PubMed ID: 25773828
[TBL] [Abstract][Full Text] [Related]
4. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
5. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
[TBL] [Abstract][Full Text] [Related]
6. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
J Clin Oncol; 2004 Aug; 22(16):3230-7. PubMed ID: 15310766
[TBL] [Abstract][Full Text] [Related]
7. [Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer].
Zhang J; Qi J; Guo Y; Guo Y; Fu W; Zhou B; Wu G; Han L; He A
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):211-8. PubMed ID: 21426662
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer.
Tao F; Ye MF; Sun AJ; Lv JQ; Xu GG; Jing YM; Wang W
World J Gastroenterol; 2014 Jul; 20(28):9564-9. PubMed ID: 25071353
[TBL] [Abstract][Full Text] [Related]
10. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.
Eguchi R; Wakabayashi I
Oncol Rep; 2020 Jul; 44(1):14-28. PubMed ID: 32319650
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma.
Wang S; Fang W
Histopathology; 2011 Jan; 58(2):217-24. PubMed ID: 21255068
[TBL] [Abstract][Full Text] [Related]
12. Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma.
Han Y; Zhang W; Liu Y
World J Surg; 2013 Oct; 37(10):2419-27. PubMed ID: 23793608
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.
Luo Z; Wu RR; Lv L; Li P; Zhang LY; Hao QL; Li W
Int J Clin Exp Pathol; 2014; 7(7):3632-46. PubMed ID: 25120740
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.
Li D; Han Z; Liu J; Zhang X; Ren J; Yan L; Liu H; Xu Z
Med Oncol; 2013 Dec; 30(4):702. PubMed ID: 23999841
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Zheng CL; Qiu C; Shen MX; Qu X; Zhang TH; Zhang JH; Du JJ
Asian Pac J Cancer Prev; 2015; 16(5):1881-95. PubMed ID: 25773840
[TBL] [Abstract][Full Text] [Related]
17. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer.
Lin YW; Li CF; Chen HY; Yen CY; Lin LC; Huang CC; Huang HY; Wu PC; Chen CH; Chen SC; Tai MH
Oral Oncol; 2012 Jul; 48(7):629-35. PubMed ID: 22361040
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.
Huang Y; Wei S; Jiang N; Zhang L; Wang S; Cao X; Zhao Y; Wang P
BMC Cancer; 2018 Dec; 18(1):1235. PubMed ID: 30526532
[TBL] [Abstract][Full Text] [Related]
20. Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients.
Zhang A; Long W; Guo Z; Liu G; Hu Z; Huang Y; Li Y; Grabinski TM; Yang J; Zhao PX; Everett AD; Zhang Y; Cao BB
J Immunol Methods; 2010 Apr; 355(1-2):61-7. PubMed ID: 20193688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
